{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:00:41Z","timestamp":1787655641723,"version":"build-2736575974"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recent studies have reported improvement of outcomes (progression-free survival, overall survival, and prolongation of androgen deprivation treatment-free survival) with stereotactic body radiotherapy (SBRT) in non-small cell lung cancer and prostate cancer. The aim of this retrospective, multicenter study (MITO RT-01) was to define activity and safety of SBRT in a very large, real-world data set of patients with metastatic, persistent, and recurrent ovarian cancer (MPR-OC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>The endpoints of the study were the rate of complete response (CR) to SBRT and the 24-month actuarial local control (LC) rate on \u201cper-lesion\u201d basis. The secondary endpoints were acute and late toxicities and the 24-month actuarial late toxicity-free survival. Objective response rate (ORR) included CR and partial response (PR). Clinical benefit (CB) included ORR and stable disease (SD). Toxicity was evaluated by the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) and Common Terminology Criteria for Adverse Events (CTCAE) scales, according to center policy. Logistic and Cox regression were used for the uni- and multivariate analysis of factors predicting clinical CR and actuarial outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CR, PR, and SD were observed in 291 (65.2%), 106 (23.8%), and 33 (7.4%) lesions, giving a rate of CB of 96.4%. Patient aged \u226460\u2009years, planning target volume (PTV) \u226418 cm3, lymph node disease, and biologically effective dose \u03b1\/\u03b210 &amp;gt;\u200970 Gy were associated with higher chance of CR in the multivariate analysis. With a median follow-up of 22 months (range, 3\u2013120), the 24-month actuarial LC rate was 81.9%. Achievement of CR and total dose &amp;gt;25 Gy were associated with better LC rate in the multivariate analysis. Mild toxicity was experienced in 54 (20.7%) patients; of 63 side effects, 48 were grade 1, and 15 were grade 2. The 24-month late toxicity-free survival rate was 95.1%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study confirms the activity and safety of SBRT in patients with MPR-OC and identifies clinical and treatment parameters able to predict CR and LC rate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0309","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T15:35:35Z","timestamp":1570721735000},"page":"e311-e320","source":"Crossref","is-referenced-by-count":92,"title":["A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups"],"prefix":"10.1093","volume":"25","author":[{"given":"Gabriella","family":"Macchia","sequence":"first","affiliation":[{"name":"Fondazione \u201cGiovanni Paolo II,\u201d Unit\u00e0 Operativa di Radioterapia, Universit\u00e0 Cattolica del Sacro Cuore, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Lazzari","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[{"name":"Division of Medical Gynecologic Oncology, IEO European Institute of Oncology, IRCCS and University of Milan-Bicocca, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Laliscia","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Division of Radiation Oncology, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Capelli","sequence":"additional","affiliation":[{"name":"Department of Human Sciences, Society and Health, University of Cassino and Southern Lazio, Cassino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Roberto","family":"D'Agostino","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiosurgery, Humanitas Clinical and Research Hospital, IRCSS, Rozzano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Deodato","sequence":"additional","affiliation":[{"name":"Fondazione \u201cGiovanni Paolo II,\u201d Unit\u00e0 Operativa di Radioterapia, Universit\u00e0 Cattolica del Sacro Cuore, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Maranzano","sequence":"additional","affiliation":[{"name":"Radiation Oncology Centre, S. Maria Hospital, Terni, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edy","family":"Ippolito","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Campus Bio-Medico University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ronchi","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Paiar","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Division of Radiation Oncology, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Scorsetti","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiosurgery, Humanitas Clinical and Research Hospital, IRCSS, Rozzano, Milan, Italy"},{"name":"Humanitas University, Department of Biomedical Sciences, Rozzano, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savino","family":"Cilla","sequence":"additional","affiliation":[{"name":"Fondazione \u201cGiovanni Paolo II,\u201d Unit\u00e0 Operativa di Fisica Medica, Universit\u00e0 Cattolica del Sacro Cuore, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Ingargiola","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Milan, Italy"},{"name":"Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Huscher","sequence":"additional","affiliation":[{"name":"U.O. di Radioterapia Oncologica \u201cGuido Berlucchi,\u201d Fondazione Poliambulanza, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Cerrotta","sequence":"additional","affiliation":[{"name":"Radiotherapy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Fodor","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Vicenzi","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapy, Azienda Ospedaliera Universitaria Ospedali Riuniti, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Russo","sequence":"additional","affiliation":[{"name":"Radiotherapy Unit, Ospedale \u201cVito Fazzi\u201d, Lecce, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Borghesi","sequence":"additional","affiliation":[{"name":"Radiotherapy Department, Azienda USL Toscana sud est, San Donato Hospital-Arezzo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Perrucci","sequence":"additional","affiliation":[{"name":"Radiation Oncology Section, University of Perugia and Perugia General Hospital, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori di Napoli, Fondazione Pascale IRCCS, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Aristei","sequence":"additional","affiliation":[{"name":"Radiation Oncology Section, University of Perugia and Perugia General Hospital, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio Giuseppe","family":"Morganti","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine \u2013 DIMES, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli, IRCCS, Unit\u00e0 Operativa Complessa Ginecologia Oncologica, Dipartimento per la Salute della Donna e del Bambino e della Salute Pubblica, Roma, Italy"},{"name":"Universit\u00e0 Cattolica del Sacro Cuore, Istituto di Ginecologia e Ostetricia, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Valentini","sequence":"additional","affiliation":[{"name":"Fondazione \u201cGiovanni Paolo II,\u201d Unit\u00e0 Operativa di Radioterapia, Universit\u00e0 Cattolica del Sacro Cuore, Campobasso, Italy"},{"name":"Universit\u00e0 Cattolica del Sacro Cuore, Istituto di Radiologia, Roma, Italy"},{"name":"Fondazione Policlinico Universitario A. Gemelli, IRCCS, Unit\u00e0 Operativa Complessa di Radioterapia, Dipartimento di Scienze Radiologiche, Radioterapiche ed Ematologiche, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Alicja","family":"Jereczek-Fossa","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Milan, Italy"},{"name":"Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Ferrandina","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli, IRCCS, Unit\u00e0 Operativa Complessa Ginecologia Oncologica, Dipartimento per la Salute della Donna e del Bambino e della Salute Pubblica, Roma, Italy"},{"name":"Universit\u00e0 Cattolica del Sacro Cuore, Istituto di Ginecologia e Ostetricia, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,10]]},"reference":[{"key":"2021122510122695700_R1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"2021122510122695700_R2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recurrent disease","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann Oncol"},{"issue":"suppl 8","key":"2021122510122695700_R3","doi-asserted-by":"crossref","first-page":"viii51","DOI":"10.1093\/annonc\/mdx441","article-title":"Treatment of recurrent ovarian cancer","volume":"28","author":"Pignata","year":"2017","journal-title":"Ann Oncol"},{"key":"2021122510122695700_R4","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/annonc\/mdz104","article-title":"Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option","volume":"30","author":"Buechel","year":"2019","journal-title":"Ann Oncol"},{"key":"2021122510122695700_R5","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122510122695700_R6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fonc.2017.00177","article-title":"Radiation treatment in women with ovarian cancer: Past, present, and future","volume":"7","author":"Fields","year":"2017","journal-title":"Front Oncol"},{"key":"2021122510122695700_R7","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.it.2018.06.001","article-title":"Immunological mechanisms responsible for radiation-induced abscopal effect","volume":"39","author":"Rodr\u00edguez-Ruiz","year":"2018","journal-title":"Trends Immunol"},{"key":"2021122510122695700_R8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19123793","article-title":"Combining PARP inhibition, radiation, and immunotherapy: A possible strategy to improve the treatment of cancer?","volume":"19","author":"C\u00e9saire","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2021122510122695700_R9","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1634\/theoncologist.2012-0092","article-title":"Review and uses of stereotactic body radiation therapy for oligometastases","volume":"17","author":"Alongi","year":"2012","journal-title":"The Oncologist"},{"key":"2021122510122695700_R10","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1200\/JCO.2008.19.6386","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for lung metastases","volume":"27","author":"Rusthoven","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122510122695700_R11","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1200\/JCO.2008.19.6329","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for liver metastases","volume":"27","author":"Rusthoven","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122510122695700_R12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fonc.2012.00181","article-title":"Phase II clinical trial of robotic stereotactic body radiosurgery for metastatic gynecologic malignancies","volume":"2","author":"Kunos","year":"2012","journal-title":"Front Oncol"},{"key":"2021122510122695700_R13","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3892\/or.2014.3412","article-title":"Volumetric intensity modulated arc therapy for stereotactic body radiosurgery in oligometastatic breast and gynecological cancers: Feasibility and clinical results","volume":"32","author":"Macchia","year":"2014","journal-title":"Oncol Rep"},{"key":"2021122510122695700_R14","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.2147\/OTT.S113119","article-title":"Volumetric modulated arc therapy for treatment of solid tumors: Current insights","volume":"10","author":"Macchia","year":"2017","journal-title":"Onco Targets Ther"},{"key":"2021122510122695700_R15","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"2021122510122695700_R16","doi-asserted-by":"crossref","first-page":"20180422","DOI":"10.1259\/bjr.20180422","article-title":"Dose escalation in extracranial stereotactic ablative radiotherapy (DESTROY-1): A multiarm Phase I trial","volume":"92","author":"Deodato","year":"2019","journal-title":"Br J Radiol"},{"key":"2021122510122695700_R17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.21037\/tlcr.2018.08.15","article-title":"Stereotactic body radiotherapy as salvage treatment for recurrence of non-small cell lung cancer after prior surgery or radiotherapy","volume":"8","author":"Milano","year":"2019","journal-title":"Transl Lung Cancer Res."},{"key":"2021122510122695700_R18","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/COC.0000000000000118","article-title":"Stereotactic Body Radiation Therapy (SBRT) combined with chemotherapy for unresected pancreatic adenocarcinoma","volume":"40","author":"Gurka","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"2021122510122695700_R19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12032-018-1190-8","article-title":"Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: A cohort study","volume":"35","author":"Mazzola","year":"2018","journal-title":"Med Oncol"},{"key":"2021122510122695700_R20","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/bjc.2017.103","article-title":"Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: New evidence from a multicentric study","volume":"116","author":"Triggiani","year":"2017","journal-title":"Br J Cancer"},{"key":"2021122510122695700_R21","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat Med"},{"key":"2021122510122695700_R22","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: A multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122510122695700_R23","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122510122695700_R24","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"2021122510122695700_R25","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/IGC.0000000000000885","article-title":"Clinical outcomes of stereotactic body radiotherapy in oligometastatic gynecological cancer","volume":"27","author":"Laliscia","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"2021122510122695700_R26","first-page":"1038","article-title":"Stereotactic body radiotherapy for lymph node relapse in Ovarian Cancer","volume":"1","author":"Trippa","year":"2016","journal-title":"Clin Oncol"},{"key":"2021122510122695700_R27","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1097\/IGC.0000000000001324","article-title":"Stereotactic Body Radiation Therapy in oligometastatic ovarian cancer: A promising therapeutic approach","volume":"28","author":"Iftode","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"2021122510122695700_R28","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ijrobp.2018.03.058","article-title":"Stereotactic Body Radiation Therapy for oligometastatic ovarian cancer: A step toward a drug holiday","volume":"101","author":"Lazzari","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122510122695700_R29","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.ijrobp.2004.07.701","article-title":"American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy","volume":"60","author":"Potters","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122510122695700_R30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.radonc.2017.05.012","article-title":"ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer","volume":"124","author":"Guckenberger","year":"2017","journal-title":"Radiother Oncol"},{"key":"2021122510122695700_R31","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/PPO.0000000000000205","article-title":"Stereotactic Body Radiotherapy for spinal metastases: Practice guidelines, outcomes, and risks","volume":"22","author":"Jabbari","year":"2016","journal-title":"Cancer J"},{"key":"2021122510122695700_R32","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.euf.2017.07.006","article-title":"Exploring all avenues for radiotherapy in oligorecurrent prostate cancer disease limited to lymph nodes: A systematic review of the role of stereotactic body radiotherapy","volume":"3","author":"Ponti","year":"2017","journal-title":"Eur Urol Focus"},{"key":"2021122510122695700_R33","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-15-0822","article-title":"New strategies in stereotactic radiotherapy for oligometastases","volume":"21","author":"Palma","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2021122510122695700_R34","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jtho.2018.06.007","article-title":"Histology, tumor volume, and radiation dose predict outcomes in NSCLC patients after stereotactic ablative radiotherapy","volume":"13","author":"Shiue","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2021122510122695700_R35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.prro.2013.01.005","article-title":"Radiation dose responses for chemoradiation therapy of pancreatic cancer: An analysis of compiled clinical data using biophysical models","volume":"4","author":"Moraru","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"2021122510122695700_R36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ctrv.2015.03.011","article-title":"The abscopal effect of local radiotherapy: Using immunotherapy to make a rare event clinically relevant","volume":"41","author":"Reynders","year":"2015","journal-title":"Cancer Treat Rev"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0309","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0309","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/2\/e311\/41919001\/oncolo_25_2_e311.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/2\/e311\/41919001\/oncolo_25_2_e311.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T05:13:58Z","timestamp":1640409238000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/2\/e311\/6443305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,10]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,10,10]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0309","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2,1]]},"published":{"date-parts":[[2019,10,10]]}}}